(Q28194547)

Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease

31 March 2020

1 reference

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

31 March 2020

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

31 March 2020

1 reference

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

31 March 2020

1 reference

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

31 March 2020

1 reference

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

31 March 2020

1 reference

Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis

31 March 2020

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

31 March 2020

1 reference

Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial

31 March 2020

1 reference

Update on clinical trials of antiplatelet therapy for cerebrovascular diseases

31 March 2020

1 reference

Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus

31 March 2020

1 reference

Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition

31 March 2020

1 reference

Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors

31 March 2020

1 reference

Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension

31 March 2020

1 reference

Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice

31 March 2020

1 reference

Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.

31 March 2020

1 reference

Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice

31 March 2020

1 reference

Underuse of aspirin in a referral population with documented coronary artery disease

31 March 2020

1 reference

Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey

31 March 2020

1 reference

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

31 March 2020

1 reference

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

31 March 2020

1 reference

PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis

31 March 2020

1 reference

Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa

31 March 2020

1 reference

Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa)

31 March 2020

1 reference

Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

31 March 2020

1 reference

Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury

31 March 2020

1 reference

Common variations in platelet glycoproteins: pharmacogenomic implications

31 March 2020

1 reference

Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.

31 March 2020

1 reference

Platelet GPIIb-IIIa blockers

31 March 2020

1 reference

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

31 March 2020

1 reference

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

31 March 2020

1 reference

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization

31 March 2020

1 reference

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

31 March 2020

1 reference

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

31 March 2020

1 reference

Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials

31 March 2020

1 reference

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

31 March 2020

1 reference

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

31 March 2020

1 reference

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

31 March 2020

1 reference

Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie.

31 March 2020

1 reference

Platelet-leukocyte-cross-talk in diabetes mellitus

31 March 2020

1 reference

Oral glycoprotein IIb/IIIa antagonists in coronary artery disease

31 March 2020

1 reference

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

31 March 2020

1 reference

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

31 March 2020

1 reference

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

31 March 2020

1 reference

Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

31 March 2020

1 reference

Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

31 March 2020

1 reference

Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes

31 March 2020

1 reference

Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa

31 March 2020

1 reference

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

31 March 2020

1 reference

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization

31 March 2020

1 reference

Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study

31 March 2020

1 reference

Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation

31 March 2020

1 reference

Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy

31 March 2020

1 reference

Need to test the arterial inflammation hypothesis

31 March 2020

1 reference

Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial

31 March 2020

1 reference

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

31 March 2020

1 reference

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

31 March 2020

1 reference

The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study

31 March 2020

1 reference

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

31 March 2020

1 reference

Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study

31 March 2020

1 reference

Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie

31 March 2020

1 reference

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

31 March 2020

1 reference

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

31 March 2020

1 reference

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting

31 March 2020

1 reference

31 March 2020

1 reference

A new name in thrombosis, ADAMTS13.

31 March 2020

1 reference

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

31 March 2020

1 reference

Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin

31 March 2020

1 reference

Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery

31 March 2020

1 reference

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

31 March 2020

1 reference

Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis

31 March 2020

1 reference

Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy

31 March 2020

1 reference

Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation

31 March 2020

1 reference

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

31 March 2020

1 reference

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

31 March 2020

1 reference

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

31 March 2020

1 reference

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

31 March 2020

1 reference

Elective stenting of the extracranial carotid arteries

31 March 2020

1 reference

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

31 March 2020

1 reference

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

31 March 2020

1 reference

Platelets, acute inflammation and inflammatory mediators

31 March 2020

1 reference

Inflammation and thrombosis: the clot thickens

31 March 2020

1 reference

Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis

31 March 2020

1 reference

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

31 March 2020

1 reference

Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein

31 March 2020

1 reference

Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets

31 March 2020

1 reference

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction

31 March 2020

1 reference

Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease

31 March 2020

1 reference

Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation

31 March 2020

1 reference

Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model

31 March 2020

1 reference

Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model

31 March 2020

1 reference

Increased levels of soluble P-selectin in hypercholesterolemic patients.

31 March 2020

1 reference

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

31 March 2020

1 reference

Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system

31 March 2020

1 reference

CD40 ligation induces tissue factor expression in human vascular smooth muscle cells

31 March 2020

1 reference

Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes

31 March 2020

1 reference

Soluble CD40L and cardiovascular risk in women

31 March 2020

1 reference

Platelet-derived CD40L: the switch-hitting player of cardiovascular disease

31 March 2020

1 reference

CD40 signaling and plaque instability

31 March 2020

1 reference

Ligation of CD40 onvascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity

31 March 2020

1 reference

CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species

31 March 2020

1 reference

Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice

31 March 2020

1 reference

Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial

31 March 2020

1 reference

Clopidogrel inhibits platelet adhesion and platelet-dependent mitogenesis in vascular smooth muscle cells

31 March 2020

1 reference

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

31 March 2020

1 reference

RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.

31 March 2020

1 reference

Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury

31 March 2020

1 reference

Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism

31 March 2020

1 reference

The P2Y12 receptor as a therapeutic target in cardiovascular disease

31 March 2020

1 reference

Defective platelet activation in G alpha(q)-deficient mice.

31 March 2020

1 reference

Identification of the platelet ADP receptor targeted by antithrombotic drugs

31 March 2020

1 reference

Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.

31 March 2020

1 reference

Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice

31 March 2020

1 reference

Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood

31 March 2020

1 reference

Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate

31 March 2020

1 reference

Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow

31 March 2020

1 reference

Resistance to thromboembolism in PI3Kgamma-deficient mice.

31 March 2020

1 reference

Cardiovascular biology. Small cells, big issues

31 March 2020

1 reference

Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.

31 March 2020

1 reference

Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism.

31 March 2020

1 reference

Antiplatelet agents in stroke prevention. combination therapy: present and future

31 March 2020

1 reference

Thrombin receptor antagonists; recent advances in PAR-1 antagonist development

31 March 2020

1 reference

Cardiovascular biology. Platelets and proteases

31 March 2020

1 reference

Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling

31 March 2020

1 reference

Role of thrombin signalling in platelets in haemostasis and thrombosis

31 March 2020

1 reference

Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin

31 March 2020

1 reference

Attacked from within, blood thins

31 March 2020

1 reference

Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation

31 March 2020

1 reference

Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides

31 March 2020

1 reference

Effect of leptin on arterial thrombosis following vascular injury in mice

31 March 2020

1 reference

Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity

31 March 2020

1 reference

Leptin promotes aggregation of human platelets via the long form of its receptor

31 March 2020

1 reference

Arp2/3 complex is required for actin polymerization during platelet shape change

31 March 2020

1 reference

Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen

31 March 2020

1 reference

Anti-human von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs.

31 March 2020

1 reference

Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.

31 March 2020

1 reference

A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation

31 March 2020

1 reference

Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.

31 March 2020

1 reference

Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction

31 March 2020

1 reference

A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor

31 March 2020

1 reference

A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V.

31 March 2020

1 reference

The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease

31 March 2020

1 reference

Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation

31 March 2020

1 reference

Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death

31 March 2020

1 reference

Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain

31 March 2020

1 reference

BIOMEDICINE: Contact-How Platelets Touch von Willebrand Factor

31 March 2020

1 reference

Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD985

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

12509756

1 reference

Consolidated OpenCitations Corpus – April 2017